Tuberin – A New Molecular Target in Alzheimer’s Disease?

被引:0
|
作者
Rosa Ferrando-Miguel
Margit Rosner
Angelika Freilinger
Gert Lubec
Markus Hengstschläger
机构
[1] Medical University of Vienna,Medical Genetics, Obstetrics and Gynecology
[2] General Hospital,Department of Pediatrics
[3] Medical University of Vienna,undefined
[4] General Hospital,undefined
来源
Neurochemical Research | 2005年 / 30卷
关键词
Alzheimer’s disease; down syndrome; hamartin; tuberin; tuberous sclerosis;
D O I
暂无
中图分类号
学科分类号
摘要
Tuberous sclerosis complex (TSC) is a common genetic disorder in which affected individuals develop mental retardation, developmental brain defects and seizures. The TSC gene products, hamartin and tuberin, form a complex, of which tuberin is assumed to be the functional component being involved in a wide variety of different cellular processes. Here we report that tuberin protein levels are decreased in the frontal cortex of patients with Alzheimer’s disease. In addition, tuberin levels are also decreased in Down syndrome brain samples positive for β-amyloid plaques and neurofibrillary tangles. Analysis of NeuN revealed that this regulation is not a consequence of differences in the amount of postmitotic neurons. This first connection of tuberin to another common disease beside TSC stimulates new approaches to investigate the molecular development and to establish new therapeutic strategies.
引用
收藏
页码:1413 / 1419
页数:6
相关论文
共 50 条
  • [1] Tuberin -: A new molecular target in Alzheimer's disease?
    Ferrando-Miguel, R
    Rosner, M
    Freilinger, A
    Lubec, G
    Hengstschläger, M
    NEUROCHEMICAL RESEARCH, 2005, 30 (11) : 1413 - 1419
  • [2] MicroRNAs as a New Target for Alzheimer's Disease Treatment
    Shademan, Behrouz
    Avci, Cigir Biray
    Karamad, Vahidreza
    Sogutlu, Fatma
    Nourazarian, Alireza
    MICRORNA, 2023, 12 (01) : 3 - 12
  • [3] New molecular approaches to Alzheimer's disease
    Di Resta, Chiara
    Ferrari, Maurizio
    CLINICAL BIOCHEMISTRY, 2019, 72 : 81 - 86
  • [4] Noradrenaline in Alzheimer's Disease: A New Potential Therapeutic Target
    Gutierrez, Irene L.
    Dello Russo, Cinzia
    Novellino, Fabiana
    Caso, Javier R.
    Garcia-Bueno, Borja
    Leza, Juan C.
    Madrigal, Jose L. M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (11)
  • [5] What is the new target inhibiting the progression of Alzheimer's disease?
    Lin Zhang
    Jing Yang
    Yunpeng Cao
    Neural Regeneration Research, 2013, (21) : 1938 - 1947
  • [6] Butyrylcholinesterase: An important new target in Alzheimer's disease therapy
    Greig, NH
    Lahiri, DK
    Sambamurti, K
    INTERNATIONAL PSYCHOGERIATRICS, 2002, 14 : 77 - 91
  • [7] Decoding Alzheimer's Disease With Depression: Molecular Insights and Therapeutic Target
    Li, Zekun
    Guo, Hongmin
    Ge, Yihao
    Li, Xiaohan
    Dong, Fang
    Zhang, Feng
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2025, 29 (05)
  • [8] Synaptotoxicity in Alzheimer's disease:: The Wnt signaling pathway as a molecular target
    Inestrosa, Nibaldo C.
    Varela-Nallar, Lorena
    Grabowski, Catalina P.
    Colombres, Marcela
    IUBMB LIFE, 2007, 59 (4-5) : 316 - 321
  • [9] EGFR is a potential dual molecular target for cancer and Alzheimer's disease
    Choi, Hee-Jeong
    Jeong, Yoo Joo
    Kim, Jieun
    Hoe, Hyang-Sook
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [10] What is the new target inhibiting the progression of Alzheimer's disease?
    Zhang, Lin
    Yang, Jing
    Cao, Yunpeng
    NEURAL REGENERATION RESEARCH, 2013, 8 (21) : 1938 - 1947